LWCFA
LSTA icon

Loring Wolcott & Coolidge Fiduciary Advisors’s Lisata Therapeutics LSTA Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2
Closed -$5 – 544
2025
Q1 		$5 Buy
+2
New +$5 ﹤0.01% 560

Other funds holding LSTA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's LSTA Position: Q2 2025 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Lisata Therapeutics (LSTA) in Q2 2025, closing a stake of 2 shares — an estimated $5 sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in LSTA in Q1 2025 and held it in 1 quarter. The position peaked at $5 in Q1 2025. 20 funds tracked by Wall St. Rank hold LSTA as of Q2 2025.

  • Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Lisata Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Loring Wolcott & Coolidge Fiduciary Advisors sold 2 Lisata Therapeutics shares in Q2 2025, an estimated $5.
  • Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Lisata Therapeutics in Q1 2025 and held it in 1 quarter.
  • Loring Wolcott & Coolidge Fiduciary Advisors's Lisata Therapeutics position peaked at $5 in Q1 2025.
  • 20 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q2 2025.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q2 2025, filed 30 Jul 2025.